Resources Here you can find resources to download and access related to ULTOMIRIS® as a treatment of adult and paediatric patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.1
Please click the links below to be redirected to a third-party website, where you can access and find more information on these selected publications.
Alexion is not the copyright holder of either the journal or the articles – such copyright(s) is/are held by the publisher(s) and/or the author(s) of the journal and/or article as appropriate. Alexion has provided the weblinks to the full article(s) merely to assist the reader and on the basis that the relevant article(s) is/are either available as ‘open access’ or via a subscription service which the reader may already subscribe to. Alexion assumes no responsibility for ascertaining if the reader has appropriate copyright licence for use of the relevant article and Alexion makes no attempt to provide any licence or permission to the reader – all such permissions and ownership rest exclusively with their owners.
Adverse Event Reporting

Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by contacting: https://contactazmedical.astrazeneca.com/

For more information on Soliris® (eculizumab), please refer to the Soliris® SmPC2
ULTOMIRIS® EU Summary of Product Characteristics available at https://www.ema.europa.eu/en/documents/product-information/ultomiris-epar-product-information_en.pdf. Last accessed: December 2024. SOLIRIS® EU Summary of Product Characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/soliris-epar-product-information_en.pdf. Last accessed: December 2024.